These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3552712)

  • 21. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein.
    Munesinghe DY; Clavijo P; Calle MC; Nussenzweig RS; Nardin E
    Eur J Immunol; 1991 Dec; 21(12):3015-20. PubMed ID: 1721025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants.
    Le TP; Church LW; Corradin G; Hunter RL; Charoenvit Y; Wang R; de la Vega P; Sacci J; Ballou WR; Kolodny N; Kitov S; Glenn GM; Richards RL; Alving CR; Hoffman SL
    Vaccine; 1998; 16(2-3):305-12. PubMed ID: 9607047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195.
    Hui GS; Chang SP; Gibson H; Hashimoto A; Hashiro C; Barr PJ; Kotani S
    J Immunol; 1991 Dec; 147(11):3935-41. PubMed ID: 1940375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
    Sherwood JA; Oster CN; Adoyo-Adoyo M; Beier JC; Gachihi GS; Nyakundi PM; Ballou WR; Brandling-Bennett AD; Schwartz IK; Were JB
    Trans R Soc Trop Med Hyg; 1991; 85(3):336-40. PubMed ID: 1949134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antibody response to the tetrapeptide repeats of Plasmodium falciparum circumsporozoite protein by splenocytes from mice infected with P. yoelii yoelii.
    Kobayashi F; Tsuji M; Weidanz WP
    J Vet Med Sci; 2001 Jul; 63(7):743-9. PubMed ID: 11503901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax.
    Collins WE; Nussenzweig RS; Ballou WR; Ruebush TK; Nardin EH; Chulay JD; Majarian WR; Young JF; Wasserman GF; Bathurst I
    Am J Trop Med Hyg; 1989 May; 40(5):455-64. PubMed ID: 2658634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic peptide immunogens eliciting antibodies to Plasmodium falciparum sporozoite and merozoite surface antigens in H-2b and H-2k mice.
    Rzepczyk CM; Csurhes PA; Lord R; Matile H
    J Immunol; 1990 Oct; 145(8):2691-6. PubMed ID: 2212657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and efficacy trials in Aotus nancymai monkeys with model compounds representing parts of a 75-kD merozoite surface antigen of Plasmodium falciparum.
    Sharma P; Ruebush TK; Campbell GH; Richman SJ; Wilkins PP; Broderson JR; Ardeshir F; Gross M; Silverman C; Skinner JC
    Am J Trop Med Hyg; 1992 Jun; 46(6):691-707. PubMed ID: 1621894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains.
    Gómez-Duarte OG; Pasetti MF; Santiago A; Sztein MB; Hoffman SL; Levine MM
    Infect Immun; 2001 Feb; 69(2):1192-8. PubMed ID: 11160021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmodium falciparum: sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine.
    Hoffman SL; Cannon LT; Berzofsky JA; Majarian WR; Young JF; Maloy WL; Hockmeyer WT
    Exp Parasitol; 1987 Aug; 64(1):64-70. PubMed ID: 2440712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.
    Lowell GH; Ballou WR; Smith LF; Wirtz RA; Zollinger WD; Hockmeyer WT
    Science; 1988 May; 240(4853):800-2. PubMed ID: 2452484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32).
    Webster HK; Boudreau EF; Pang LW; Permpanich B; Sookto P; Wirtz RA
    J Clin Microbiol; 1987 Jun; 25(6):1002-8. PubMed ID: 2439533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of Plasmodium falciparum sexual stage antigens: implications for the design of a transmission blocking vaccine.
    Kaslow DC
    Immunol Lett; 1990 Aug; 25(1-3):83-6. PubMed ID: 1704352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum.
    Ballou WR; Rothbard J; Wirtz RA; Gordon DM; Williams JS; Gore RW; Schneider I; Hollingdale MR; Beaudoin RL; Maloy WL
    Science; 1985 May; 228(4702):996-9. PubMed ID: 2988126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmodium falciparum: administration of anti-sporozoite antibodies during sporogony results in production of sporozoites which are not neutralized by human anti-circumsporozoite protein vaccine sera.
    do Rosario VE; Appiah A; Vaughan JA; Hollingdale MR
    Trans R Soc Trop Med Hyg; 1989; 83(3):305-7. PubMed ID: 2694460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformation and immunogenicity of engineered repeating segment of the circumsporozoite surface protein of Plasmodium falciparum.
    Armah GE; Nishikawa S; Miki S; Omata Y; Nakabayashi T; Tomita K
    Mol Biochem Parasitol; 1990 Jan; 38(1):135-40. PubMed ID: 2181302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro.
    Mazier D; Mellouk S; Beaudoin RL; Texier B; Druilhe P; Hockmeyer W; Trosper J; Paul C; Charoenvit Y; Young J
    Science; 1986 Jan; 231(4734):156-9. PubMed ID: 3510455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.